Gastroparesis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Gastroparesis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

  • August 2022 •
  • 143 pages •
  • Report ID: 6313796 •
  • Format: PDF
The global gastroparesis drugs market size reached US$ 5.9 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 7.8 Billion by 2027, exhibiting a growth rate (CAGR) of 5.15% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Gastroparesis, also known as stomach paralysis, is a medical condition that affects the normal and spontaneous movement of the muscles in the stomach. It interferes with the digestion process and causes nausea, vomiting, abdominal pain, and problems with maintaining blood sugar levels and nutrition absorption. At present, it is treated under the guidance of doctors using drugs, such as domperidone, metoclopramide, erythromycin, diphenhydramine, ondansetron, and prochlorperazine.

Gastroparesis Drugs Market Trends:
Due to rapid urbanization, sedentary lifestyles and the growing number of individuals who drink and smoke regularly, there is a significant rise in the prevalence of diabetes across the globe. This, in confluence with the increasing geriatric population, which is relatively more susceptible to developing gastroparesis, represents one of the key factors bolstering the growth of the market. In addition, gastroparesis drugs aid in enhancing gastrointestinal motility by improving the frequency of contraction. As a result, they are extensively being utilized for treating idiopathic gastroparesis, which causes severe vomiting, nausea, and upper abdominal pain. This, along with a considerable rise in the number of individuals developing gastroparesis after the vague nerve and its branches are damaged via surgical operations, are also contributing to market growth. Furthermore, leading manufacturers are continuously funding research and development (R&D) projects to introduce new approaches to the existing drug therapy. They are also developing advanced and effective drugs that can be administered via the nasal cavity for individuals who are experiencing symptoms of gastroparesis, which is creating a favorable market outlook. Other major factors, including the improving healthcare infrastructure and the escalating demand for user-friendly drugs, are anticipated to impel the growth of the market.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global gastroparesis drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on disease type, drug class and distribution channel.

Breakup by Disease Type:
Diabetic Gastroparesis
Idiopathic Gastroparesis
Post-surgical Gastroparesis
Others

Breakup by Drug Class:
Prokinetic Agents
Antiemetic Agents
Botulinum Toxin Injections

Breakup by Distribution Channel:
Hospitals and Clinics
Pharmacies
Online Stores

Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Theravance Biopharma.



Key Questions Answered in This Report:

How has the global gastroparesis drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global gastroparesis drugs market?
What are the key regional markets?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global gastroparesis drugs market and who are the key players?
What is the degree of competition in the industry?